AstraZeneca vaccine co-developer responds to recent concerns: “Very reassuring evidence”

There is “very reassuring evidence that there is no increase in the blood clot phenomenon here in the UK, where most of the doses in Europe have been administered so far,” said Monday to the BBC Professor Andrew Pollard, director of the Oxford Vaccine Group which developed the vaccine with AstraZeneca.

He stressed the importance of continuing vaccination against the coronavirus, a disease which presents a “huge risk” to health.

In a statement released on Sunday, AstraZeneca said that “a careful review of all available safety data on more than 17 million people vaccinated in the European Union and the UK” with its vaccine “has yielded no evidence of an increased risk of pulmonary embolism, deep vein thrombosis (DVT) or thrombocytopenia in any particular age group, gender, lot or country ”.

“About 17 million people in the European Union and the United Kingdom have now received our vaccine, and the number of blood clot cases reported in this group is lower than the hundreds of cases one would expect in the general population “, compared Dr. Ann Taylor, chief medical officer, in this release.

The Dutch government decided on Sunday to suspend the use of this vaccine as a precaution, until March 28 inclusive, after “possible side effects” were reported in Denmark and Norway with the AstraZeneca vaccine, with no proven link to this. stage, according to the Ministry of Health.

Earlier in the day, Ireland had taken the same decision after the report in Norway of four new serious cases of blood clots in vaccinated adults.

Norway, which also reported skin hemorrhages in vaccinated young people on Saturday, suspended the vaccine last week, as did Denmark, Iceland and Bulgaria.

Website design By BotEap.com

Add a Comment

Your email address will not be published.